Sotatercept
Drug
Celgene Corporation
Total Payments
$816,860
Transactions
97
Doctors
22
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $78,282 | 5 | 0 |
| 2018 | $348,045 | 17 | 6 |
| 2017 | $390,534 | 75 | 19 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $761,434 | 58 | 93.2% |
| Consulting Fee | $28,250 | 7 | 3.5% |
| Travel and Lodging | $17,471 | 19 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,198 | 6 | 1.1% |
| Food and Beverage | $506.13 | 7 | 0.1% |
Payments by Type
Research
$761,434
58 transactions
General
$55,426
39 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ACE-011-MDS-001 | Celgene Corporation | $140,213 | 13 |
| ACE-011-MF-PI-0005 | Celgene Corporation | $116,180 | 12 |
| ACE-011-DBA-PI-0001 - Phase-2, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults with Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia | Celgene Corporation | $110,468 | 0 |
| ACE-011-MM-PI-0003 - A Phase 1 Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide or Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multipl | Celgene Corporation | $95,888 | 0 |
| ACE-011-MDS-001 - An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-p | Celgene Corporation | $70,216 | 3 |
| ACE-011-MF-PI-0005 - A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA | Celgene Corporation | $62,425 | 0 |
| ACE-011-MM-PI-0003 | Celgene Corporation | $59,187 | 0 |
| A Phase 1 Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide or Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (ACE-011-MM-PI-0003) | Celgene Corporation | $31,649 | 0 |
| Phase-2, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults with Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia (ACE-011-DBA-PI-0001) | Celgene Corporation | $26,556 | 0 |
| ACE-011-MDS-011 | Celgene Corporation | $22,500 | 1 |
| A PHASE-2, PROSPECTIVE, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND EFFICACY OF SOTATERCEPT (ACE-011) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) -ASSOCIATED MYELOFIBROSIS AND ANEMIA (ACE-011-MF-PI-0005) | Celgene Corporation | $15,606 | 0 |
| ACE-011-DBA-PI-0001 | Celgene Corporation | $6,076 | 0 |
| An Open-label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) (ACE-011-MDS-001) | Celgene Corporation | $4,470 | 0 |
Top Doctors Receiving Payments for Sotatercept
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $686,571 | 30 |
| , MD | Internal Medicine | Stanford, CA | $31,315 | 19 |
| , M.D | Hematology & Oncology | Rochester, NY | $22,500 | 1 |
| , MD | Hematology & Oncology | Denver, CO | $16,520 | 4 |
| , M.D | Hematology & Oncology | Nashville, TN | $13,265 | 4 |
| , MD | Hematology & Oncology | New Hyde Park, NY | $5,838 | 2 |
| , MD | Hematology | San Diego, CA | $4,567 | 6 |
| , MD | Anesthesiology | Durham, NC | $4,051 | 5 |
| , M.D | Anesthesiology | New Hyde Park, NY | $3,170 | 2 |
| , MD | Hematology & Oncology | Philadelphia, PA | $3,125 | 1 |
| , M.D | Medical Oncology | Cambridge, MA | $2,866 | 1 |
| , MD | Nephrology | Saint Louis, MO | $2,866 | 1 |
| Hartmut Malluche | — | Lexington, KY | $2,866 | 1 |
| , M.D | Hematology & Oncology | Boston, MA | $1,734 | 2 |
| , M.D | Hematology | Cincinnati, OH | $1,734 | 2 |
| , M.D | Hematology & Oncology | Nashville, TN | $1,734 | 2 |
| , MD | Medical Oncology | Baltimore, MD | $1,734 | 2 |
| , MD | Hematology | Tampa, FL | $1,734 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $1,734 | 2 |
| , MD00022875 | Hematology & Oncology | Yakima, WA | $1,734 | 2 |
| , MD | Hematology & Oncology | Cleveland, OH | $1,734 | 2 |
| , MD | Hematology & Oncology | New York, NY | $1,734 | 2 |
| , M.D | Medical Oncology | Houston, TX | $1,734 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $816,860
Product Information
- Type Drug
- Total Payments $816,860
- Total Doctors 22
- Transactions 97
About Sotatercept
Sotatercept is a drug associated with $816,860 in payments to 22 healthcare providers, recorded across 97 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $78,282 was paid across 5 transactions to 0 doctors.
The most common payment nature for Sotatercept is "Unspecified" ($761,434, 93.2% of total).
Sotatercept is associated with 13 research studies, including "ACE-011-MDS-001" ($140,213).